Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

Creative Commons License

Chan A., Moy B., Mansi J., Ejlertsen B., Holmes F. A., Chia S., ...More

CLINICAL BREAST CANCER, vol.21, no.1, pp.80-98, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 1
  • Publication Date: 2021
  • Doi Number: 10.1016/j.clbc.2020.09.014
  • Journal Name: CLINICAL BREAST CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.80-98
  • Keywords: Adjuvant therapy, Disease-free survival, Distant disease-free survival, Neoadjuvant therapy, Overall survival, PLUS ADJUVANT CHEMOTHERAPY, DOUBLE-BLIND, TRASTUZUMAB, THERAPY, MULTICENTER, SURVIVAL, OUTCOMES
  • Dokuz Eylül University Affiliated: Yes

Abstract

In the patient population with early-stage human epidermal growth factor receptor 2-positive/hormone receptor-positive breast cancer who initiate neratinib within 1 year of trastuzumab-based therapy, the absolute 5-year invasive disease-free survival benefit versus placebo is 5.1%, and absolute 8-year overall survival benefit is 2.1%. Among those with residual disease after neoadjuvant therapy (non-pathologic complete response), absolute gains with neratinib are 7.4% and 9.1%, respectively.